Citable company snapshot
ResMed's latest SEC-sourced 2026-03-31 period shows $1.43B in revenue and $398.73M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $1.43B | $1.42B | +0.6% |
| xbrl:GrossProfit | Mar 31, 2026 | $890.98M | $878.72M | +1.4% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $499.81M | $491.66M | +1.7% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $398.73M | $392.59M | +1.6% |
| standalone via YTD differencing | Dec 31, 2025 | $339.75M | $457.32M | -25.7% |
| Free Cash Flow (computed) | Dec 31, 2025 | $311.21M | $414.36M | -24.9% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 1, 2026; accession 0000943819-26-000025.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
